These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8674902)

  • 41. The long-term benefits of early intensive therapy in chronic diseases-the legacy effect.
    Zoccali C; Mallamaci F; Tripepi G; Fu EL; Stel VS; Dekker FW; Jager KJ
    Clin Kidney J; 2023 Nov; 16(11):1917-1924. PubMed ID: 37915902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of glucose control in people with type 2 diabetes: a review and consensus.
    Woo JT; Park KS; Byun DW; Ko KS; Chung YS; Kim DM; Park TS; Cha BS; Lee IK; Park JY; Son HS; Lee MK; Kim KW; Son HY
    Korean Diabetes J; 2010 Feb; 34(1):16-20. PubMed ID: 20532015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. One size does not fit all glycemic targets for type 2 diabetes.
    Pozzilli P; Strollo R; Bonora E
    J Diabetes Investig; 2014 Mar; 5(2):134-41. PubMed ID: 24843750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials.
    Couri CE; Voltarelli JC
    Diabetol Metab Syndr; 2009 Oct; 1(1):19. PubMed ID: 19835616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypothesis: Intensive insulin therapy-induced mortality is due to excessive serotonin autoinhibition and autonomic dysregulation.
    Das UN
    World J Diabetes; 2010 Sep; 1(4):101-8. PubMed ID: 21537434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunotherapy at clinical diagnosis of insulin-dependent diabetes: an approach still worth considering.
    Pozzilli P; Maclaren NK
    Trends Endocrinol Metab; 1993 Apr; 4(3):101-5. PubMed ID: 18407142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intensive Glycemic Control Improves Long-term Renal Outcomes in Type 2 Diabetes in the Veterans Affairs Diabetes Trial (VADT).
    Agrawal L; Azad N; Bahn GD; Reaven PD; Hayward RA; Reda DJ; Emanuele NV;
    Diabetes Care; 2019 Nov; 42(11):e181-e182. PubMed ID: 31548245
    [No Abstract]   [Full Text] [Related]  

  • 48. The management of adult diabetes.
    Epstein HH
    Can Fam Physician; 1973 Oct; 19(10):69-72. PubMed ID: 20468987
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diabetes control and cardiovascular risk, Part II: Intensive glucose control--UKPDS follow-up.
    Liebson PR
    Prev Cardiol; 2009; 12(1):51-8. PubMed ID: 19301692
    [No Abstract]   [Full Text] [Related]  

  • 50. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.
    Am J Ophthalmol; 2000 May; 129(5):704-5. PubMed ID: 10844091
    [No Abstract]   [Full Text] [Related]  

  • 51. Correction: Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy.
    N Engl J Med; 2000 May; 342(18):1376. PubMed ID: 10793172
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy of Artificial Pancreas Use in Patients With Type 2 Diabetes Using Intensive Insulin Therapy: A Randomized Crossover Pilot Trial.
    Taleb N; Carpentier AC; Messier V; Ladouceur M; Haidar A; Rabasa-Lhoret R
    Diabetes Care; 2019 Jul; 42(7):e107-e109. PubMed ID: 31221705
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy of Periodic Intensive Insulin Therapy on secondary complications of diabetes warrants larger prospective randomized clinical trials.
    Lakey J
    Curr Ther Res Clin Exp; 2019; 91():23. PubMed ID: 31871503
    [No Abstract]   [Full Text] [Related]  

  • 54. Correction to: Effects of Early Intensive Insulin Therapy on Endothelial Progenitor Cells in Patients with Newly Diagnosed Type 2 Diabetes.
    Zhang W; Wang H; Liu F; Ye X; Tang W; Zhang P; Gu T; Zhu D; Bi Y
    Diabetes Ther; 2022 Apr; 13(4):691. PubMed ID: 35286608
    [No Abstract]   [Full Text] [Related]  

  • 55. Diabetes: early initiation of intensive therapy might benefit children with type 2 diabetes mellitus.
    Barranco C
    Nat Rev Endocrinol; 2012 May; 8(7):382. PubMed ID: 22614716
    [No Abstract]   [Full Text] [Related]  

  • 56. Periodic Intensive Insulin Therapy Remains Experimental.
    Chang A; Philis-Tsimikas A
    Curr Ther Res Clin Exp; 2019; 91():24. PubMed ID: 31871504
    [No Abstract]   [Full Text] [Related]  

  • 57. THE ESSENTIAL POINTS IN THE TREATMENT OF DIABETES WITH INSULIN.
    Sansum WD; Blatherwick NR
    Cal State J Med; 1923 Oct; 21(10):420-3. PubMed ID: 18739109
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
    Schweizer A; Foley JE; Kothny W; Ahrén B
    Vasc Health Risk Manag; 2013; 9():57-64. PubMed ID: 23431062
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
    Scott LJ; Spencer CM
    Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus.
    Evans A; Krentz AJ
    Drug Saf; 1999 Jul; 21(1):7-22. PubMed ID: 10433350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.